Ovarian cancer stem cells (mainly the CD44+/CD133+ or the CD44+/CD117+ subpopulations) were discovered in ovarian cancer tissues in recent years; therefore, there are new demands for targeted ovarian cancer therapy.1, 4 Because OCSCs are resistant to various tumour chemotherapeutic drugs, targeted killing of this cell population is difficult.1, 4 However, on the other hand, the discovery of one type of tumour treatment method that has high specificity for targeting OCSCs will be very meaningful for the inhibition of ovarian cancer metastasis and recurrence. Here, KIT is linked to ovarian carcinoma.